P10636

※ Protein Information

Tag	Content
UniProt Accession	TAU_HUMAN; P10636;
Entrez ID	4137
GenBank Protein ID	NM_001123066.3; NM_001123067.3; NM_001203252.1; NM_005910.5; NM_016834.4; NM_016835.4; NM_016841.4;
GenBank Nucleotide ID	NP_001116538.2; NP_001116539.1; NP_001190181.1; NP_005901.2; NP_058518.1; NP_058519.3; NP_058525.1;
Protein Name	Microtubule-associated protein tau (Neurofibrillary tangle protein) (Paired helical filament-tau) (PHF-tau)
Gene Name	MAPT; MAPTL; MTBT1; TAU
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. Functional Description Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
Sequence (Fasta)	MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG 60 SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG 120 HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG 180 GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA 240 QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE 300 FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEGPEARGP SLGEDTKEAD LPEPSEKQPA 360 AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKHPTPGSS 420 DPLIQPSSPA VCPEPPSSPK YVSSVTSRTG SSGAKEMKLK GADGKTKIAT PRGAAPPGQK 480 GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP 540 KKVAVVRTPP KSPSSAKSRL QTAPVPMPDL KNVKSKIGST ENLKHQPGGG KVQIINKKLD 600 LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSKCG SLGNIHHKPG GGQVEVKSEK 660 LDFKDRVQSK IGSLDNITHV PGGGNKKIET HKLTFRENAK AKTDHGAEIV YKSPVVSGDT 720 SPRHLSNVSS TGSIDMVDSP QLATLADEVS ASLAKQGL 759 Fasta Sequence >P10636\|MAPT; MAPTL; MTBT1; TAU\|Homo sapiens (Human) MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL

※ PTM-Disease Association

Num	PTM	Disease	Cell Type	Type	PTM Site	PMID
1	Methylation	Alzheimer's disease		D		23943618; 3779734
1	[Reference]: We propose that alterations in the membrane localization of PP2A and Tau following down-regulation of LCMT1 may lead to PP2A and Tau dysfunction in AD.
2	Phosphorylation	Alzheimer's disease		P		23638980
2	[Reference]: ecovery is 90% for a pure phosphopeptide.
3	Glycosylation	Alzheimer's disease		P		24279329
3	[Reference]: The major pathological hallmarks in AD are neurofibrillary tangles and amyloid plaques. Neurofibrillary tangles are composed of phosphorylated tau, and the plaques are composed of amyloid -peptide (A), which is generated from amyloid precursor?protein?(APP). Defects in glycosylation of APP, tau and other proteins have been reported in AD
4	O-linked glycosylation	Alzheimer's disease		P		24144743
4	[Reference]: XXD can regulate the expression of OGT and O-GlcNAc glycosidase to enhance O-GlcNAc glycosylation of tau proteins in the hippocampus of SAD rats
5	Glycosylation	Sporadic Alzheimer disease		P		24024334
5	[Reference]: XXD can significantly improve O-GlcNAc glycosylation level of tau proteins in the hippocampus of SAD rats, which maybe inhibit hyperphosphorylation of tau proteins on key sites and its toxicity, and prevent the pathological process of SAD.
6	Serine Phosphorylation	Diabetes mellitus		U		19659459
6	[Reference]: Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.
7	Phosphorylation	Alzheimer's disease		U		24411482; 24319659; 24497730
7	[Reference]: Hyperphosphorylation and aggregation of TAU cause neurofibrillary pathologies, including tangles and neuropil threads that are often seen in brains of patients with Alzheimer?? disease (AD)
8	Phosphorylation	Type 2 diabetic		U		24411482
8	[Reference]: Notably, patients with T2D have increased levels of hyperphosphorylated tau in their brains
9	Serine Phosphorylation	Alzheimer's disease		U	S	23726868
9	[Reference]: On the other hand, in 3xTg-AD mice treated with spa-water (12 ml/kg i.p.) the phosphorylation/expression level of the amyloid/tau cascade proteins was impressively decreased, as compared with that of saline-treated 3xTg-AD mice
10	Dephosphorylation	Alzheimer's disease		U		3950283; 24618580
10	[Reference]: tau was enriched in the neurites and sparse in the soma of SH-SY5Y cells induced to differentiate by retinoic acid (RA). Treatment with RA also increased total tau?protein?levels but decreased expression of tau phosphorylated at Ser262 as determined by Western blot. Both effects were further enhanced by subsequent BDNF treatment
11	Lysine Methylation	Alzheimer's disease		P	K24	24869773
11	[Reference]: Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity
12	Threonine Phosphorylation	Alzheimer's disease		P	T39	15517432
12	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
13	Lysine Methylation	Alzheimer's disease		P	K44	2203387; 24869773
13	[Reference]: Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity
14	Serine Phosphorylation	Alzheimer's disease		P	S46	15517432
14	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
15	Serine Phosphorylation	Progressive supranuclear palsy		U	S46	18315566
15	[Reference]: Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.
16	Threonine Phosphorylation	Alzheimer's disease		A	T50	15517432
16	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
17	Lysine Methylation	Alzheimer's disease		P	K67	24869773
17	[Reference]: Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity
18	Threonine Phosphorylation	Alzheimer's disease		P	T69	15517432
18	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
19	Threonine Phosphorylation	Alzheimer's disease		P	T123	15517432
19	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
20	Serine Phosphorylation	Alzheimer's disease		A	S131	15517432
20	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
21	Threonine Phosphorylation	Alzheimer's disease		A	T135	15517432
21	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
22	Serine Phosphorylation	Alzheimer's disease		P	S137	15517432
22	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
23	Threonine Phosphorylation	Alzheimer's disease		P	T153	15517432
23	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
24	Lysine Methylation	Alzheimer's disease		P	K163	22033876
24	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
25	Lysine Methylation	Alzheimer's disease		P	K174	22033876
25	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
26	Threonine Phosphorylation	Alzheimer's disease		P	T175	15517432
26	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
27	Lysine Methylation	Alzheimer's disease		P	K180	22033876
27	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
28	Threonine Phosphorylation	Alzheimer's disease		P	T181	15517432; 23439248
28	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
29	Threonine Phosphorylation	Corticobasal syndrome		U	T181	20836136
29	[Reference]: Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome
30	Serine Phosphorylation	Alzheimer's disease		A	S184	15517432
30	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
31	Lysine Methylation	Alzheimer's disease		P	K190	24869773
31	[Reference]: Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity
32	Serine Phosphorylation	Alzheimer's disease		A	S195	15517432
32	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
33	Serine Phosphorylation	Alzheimer's disease		P	S198	15517432
33	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
34	Serine Phosphorylation	Alzheimer's disease		P	S199	15517432
34	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
35	Serine Phosphorylation	Alzheimer's disease		P	S202	15517432
35	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
36	Threonine Phosphorylation	Alzheimer's disease		P	T205	15517432
36	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
37	Serine Phosphorylation	Alzheimer's disease		P	S208	15517432
37	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
38	Serine Phosphorylation	Alzheimer's disease		P	S210	15517432
38	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
39	Threonine Phosphorylation	Alzheimer's disease		P	T212	15517432
39	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
40	Serine Phosphorylation	Alzheimer's disease		P	S214	15517432
40	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
41	Threonine Phosphorylation	Alzheimer's disease		P	T217	15517432
41	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
42	Threonine Phosphorylation	Alzheimer's disease		P	T231	24660612; 15517432; 23262393
42	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
43	Serine Phosphorylation	Alzheimer's disease		P	S235	15517432
43	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
44	Serine Phosphorylation	Alzheimer's disease		P	S237	15517432
44	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
45	Serine Phosphorylation	Alzheimer's disease		P	S238	15517432
45	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
46	Serine Phosphorylation	Alzheimer's disease		P	S241	15517432
46	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
47	Lysine Methylation	Alzheimer's disease		P	K254	22033876
47	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
48	Serine Phosphorylation	Alzheimer's disease	tumor tissue	U	S262	23001711
48	[Reference]: Enhanced phosphorylation of tau on Ser(262) is detected early in the course of the disease and may have a role in the formation of tangles
49	Lysine Methylation	Alzheimer's disease		P	K267	22033876
49	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
50	Serine Phosphorylation	Alzheimer's disease		P	S285	15517432
50	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
51	Lysine Methylation	Alzheimer's disease		P	K290	22033876
51	[Reference]: Together these data reveal that PHF-tau is monomethylated in vivo, and that the major occupied sites distribute across protein segments known to mediate tau-protein interactions
52	Serine Phosphorylation	Alzheimer's disease		P	S305	15517432
52	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
53	Serine Phosphorylation	Alzheimer's disease		P	S324	15517432
53	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
54	Serine Phosphorylation	Alzheimer's disease		P	S352	15517432
54	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
55	Serine Phosphorylation	Alzheimer's disease		P	S356	15517432
55	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
56	Threonine Phosphorylation	Alzheimer's disease		P	T373	15517432
56	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
57	Serine Phosphorylation	Alzheimer's disease		P	S396	15517432; 23262393
57	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.;High-dose iron treatment markedly increased the levels of tau phosphorylation at the sites of Thr205, Thr231 and Ser396, whereas highly induced tau phosphorylation was abolished by intranasal administration of DFO in APP/PS3 transgenic mice.
58	Serine Phosphorylation	Alzheimer's disease		P	S400	15517432
58	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
59	Threonine Phosphorylation	Alzheimer's disease		P	T403	15517432
59	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
60	Threonine Phosphorylation	Alzheimer's disease		P	T404	15517432
60	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
61	Serine Phosphorylation	Alzheimer's disease		A	S409	15517432
61	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies
62	Serine Phosphorylation	Alzheimer's disease		P	S412	15517432
62	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
63	Serine Phosphorylation	Alzheimer's disease		A	S413	15517432
63	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies
64	Serine Phosphorylation	Alzheimer's disease		P	S416	15517432
64	[Reference]: Total tau and phosphorylated tau levels in cerebrospinal fluid as a diagnostic biomarkers are also reviewed. Analyses of the current advances in tau modifications suggest that intervention addressing these abnormalities may offer promising therapeutic opportunities to prevent and treat neurofibrillary degeneration of AD and other tauopathies.
65	Threonine Phosphorylation	Progressive supranuclear palsy		U	T498	18315566
65	[Reference]: Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.
66	Threonine Phosphorylation	Frontotemporal lobar degeneration		U	T498	15136685
66	[Reference]: Increased in early-onset Alzheimer disease patients, as compared to frontotemporal lobar degeneration or normal control patients. AD was highest, and FTLD higher than normal controls.
67	Threonine Phosphorylation	Alzheimer's disease		U	T498	19659459; 17314187; 21828286; 15136685; 12614922; 9832145
67	[Reference]: Increased in early-onset Alzheimer disease patients, as compared to frontotemporal lobar degeneration or normal control patients. AD was highest, and FTLD higher than normal controls.;;;;;
68	Tyrosine Phosphorylation	Alzheimer's disease		U	Y514	9832145
68	[Reference]: New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.
69	Serine Phosphorylation	Alzheimer's disease		U	S515	15126504; 9832145
69	[Reference]: Remarkably knock-down of WOX1 expression by small interfering RNA in neuroblastoma SK-N-SH cells spontaneously induced Tau phosphorylation at Thr212/Thr231 and Ser515/Ser516, enhanced phosphorylation of glycogen synthase kinase 3beta (GSK-3beta) and ERK, and enhanced NFT formation.
70	Serine Phosphorylation	Diabetes mellitus		U	S519	19659459
70	[Reference]: Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.
71	Serine Phosphorylation	Alzheimer's disease		U	S527	9832145
71	[Reference]: New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.
72	Threonine Phosphorylation	Alzheimer's disease		U	T529	15126504; 21828286; 19451179; 19821112; 9832145; 18725412
72	[Reference]: Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer's disease.
73	Threonine Phosphorylation	Progressive supranuclear palsy		U	T548	18315566
73	[Reference]: Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.
74	Threonine Phosphorylation	Alzheimer's disease		U	T548	22278060; 12766916; 15126504; 21828286; 19821112; 9832145; 15883264; 15324364
74	[Reference]: potential biomarker for Alzheimer's as distinct from other dementias. Phosphorylation occurs at early and later stages of AD.;AD diagnostic tool
75	Serine Phosphorylation	Diabetes mellitus		U	S579	19659459
75	[Reference]: Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.
76	Serine Phosphorylation	Alzheimer's disease		U	S713	19659459; 11943712; 19451179; 21828286; 9832145; 8318230; 18725412; 20110615; 11034902
76	[Reference]: ;S396 and S304 are hyperphosphorylated in the CSF of AD patients as compared with normal controls. useful diagnostic marker of AD;;;;Antibodies to phosphorylated S396/404 stain brain sections early in the disease. ;;;
77	Serine Phosphorylation	Diabetes mellitus		U	S713	19659459
77	[Reference]: Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.
78	Serine Phosphorylation	Progressive supranuclear palsy		U	S713	18315566
78	[Reference]: Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.
79	Serine Phosphorylation	Progressive supranuclear palsy		U	S717	18315566
79	[Reference]: Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats.
80	Threonine Phosphorylation	Alzheimer's disease		U	T720	9832145; 21828286
80	[Reference]: New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.
81	Serine Phosphorylation	Diabetes mellitus		U	S739	19659459
81	[Reference]: Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease.

PTMD Annotation Information

※ Protein Information

Functional Description

Fasta Sequence

※ PTM-Disease Association